A Phase 1, First-in-Human, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 in Subjects With Advanced Solid Tumors With a Specific KRAS Mutation
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Amgen, Inc.
Start Date
January 28, 2019
End Date
January 27, 2024
Administered By
Duke Cancer Institute
Awarded By
Amgen, Inc.
Start Date
January 28, 2019
End Date
January 27, 2024